TABLE 3.
Running clinical trial studies for validation of Favipiravir (https://clinicaltrials.gov/ct 2/results).
| Sl. No. | Title | NCT No. | Therapeutic Dose | Phase | Location |
|---|---|---|---|---|---|
| 1 | Safety and efficacy of Favipiravir in Management of COVID-19 | NCT04349241 | Loading dose: 1,600 mg (Every 12h), Day 2–10 (1,200 mg) | 3 | Egypt |
| 2 | Safety estimation of Favipiravir for COVID-19– management | NCT04336904 | Loading dose: Day 1: 1,800 mg (BID) Days 2–14: 600 mg (TID) |
3 | Italy |
| 3 | Favipiravir efficacy in hospitalized SARS-CoV-2 patients | NCT04359615 | Not specified | 4 | Iran |
| 4 | Oral injection of Favipiravir against mild infection | NCT04346628 | Loading dose: 1,800 mg (Day 1 BID), Day 2–9 (800 mg BID) | 2 | U.S. |
| 5 | Favipiravir use in SARS-CoV-2 patients | NCT04358549 | Loading dose: 1,800 mg (Day 1- twice a day), Day 2–14: 1,800 mg (twice a day) | 2 | U.S. |